1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 65, 327, 273, 23, 249, 46 and 12 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 16, 22, 51 and 4 molecules, respectively.
Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Non-Small Cell Lung Cancer - Overview
- Non-Small Cell Lung Cancer - Therapeutics Development
- Non-Small Cell Lung Cancer - Therapeutics Assessment
- Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
- Non-Small Cell Lung Cancer - Drug Profiles
- Non-Small Cell Lung Cancer - Dormant Projects
- Non-Small Cell Lung Cancer - Discontinued Products
- Non-Small Cell Lung Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
- Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by 4D Pharma Plc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by A&G Pharmaceutical Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by ABM Therapeutics Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by AC Bioscience SA, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by ACEA Therapeutics Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Achilles Therapeutics Ltd, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by AcuityBio Corp, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by ADC Therapeutics SA, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Advanced BioDesign, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Adze Biotechnology Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Agilvax Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Agios Pharmaceuticals Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by AIM ImmunoTech Inc, H1 2020
- Non-Small Cell Lung Cancer - Pipeline by Akeso Inc, H1 2020
List of Figures
- Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- 4D Pharma Plc
- 4SC AG
- A&G Pharmaceutical Inc
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- Ability Pharmaceuticals SL
- ABM Therapeutics Inc
- AC Bioscience SA
- ACEA Therapeutics Inc
- Achilles Therapeutics Ltd
- AcuityBio Corp
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Aduro BioTech Inc
- Advanced BioDesign
- Advaxis Inc
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Agenus Inc
- Agilvax Inc
- Agios Pharmaceuticals Inc
- AIM ImmunoTech Inc
- Akeso Inc
- Alethia Biotherapeutics Inc
- Alkermes Plc
- Alligator Bioscience AB
- Allist Shanghai Pharmaceutical Technology Co Ltd
- Almac Discovery Ltd
- Alpha Biopharma
- Alphamab Oncology
- Altum Pharmaceuticals Inc
- ALX Oncology Inc
- amcure GmbH
- Amgen Inc
- AmMax Bio Inc
- Amphivena Therapeutics Inc
- Andarix Pharmaceuticals Inc
- Anew Oncology Inc
- AnHeart Therapeutics Inc
- Anhui Anke Biotechnology (Group) Co Ltd
- Antapodia Therapeutics Inc
- Antengene Corp
- AP Biosciences Inc
- Apexigen Inc
- Apollomics Inc
- Apotex Inc
- Aprea Therapeutics AB
- Aptarion biotech AG
- Araxes Pharma LLC
- Arch Oncology Inc
- Arcus Biosciences Inc
- Aro Biotherapeutics Co
- Arvinas Inc
- Asana BioSciences LLC
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Astellas Pharma Inc
- AstraZeneca Plc
- Atreca Inc
- AUM Biosciences Pte Ltd
- Aurigene Discovery Technologies Ltd
- Aurobindo Pharma Ltd
- Axelar AB
- Basilea Pharmaceutica Ltd
- Batu Biologics Inc
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- Beijing Biostar Technologies Ltd
- Beijing Eastern Biotech Co Ltd
- Beijing Hanmi Pharmaceutical Co Ltd
- Beijing Kawin Technology Share-Holding Co Ltd
- Beijing Luzhu Biotechnology Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Beijing Pearl Biotechnology LLC
- BerGenBio ASA
- Beta Pharma Inc
- Betta Pharmaceuticals Co Ltd
- BeyondSpring Inc
- Bicycle Therapeutics Plc
- Binjiang Pharma, Inc.
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- BioAtla LLC
- Biocad
- BIOCND Inc
- Biocon Ltd
- Biohaven Pharmaceutical Holding Company Ltd
- BioIntegrator Ltd
- BioInvent International AB
- BioLineRx Ltd
- BioMarck Pharmaceuticals Ltd
- BioMed Valley Discoveries Inc
- BioNTech SE
- Biosion Inc
- Biothera Pharmaceutical Inc
- Bioven Group
- BioXpress Therapeutics SA
- BJ Bioscience Inc
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Boston Biomedical Inc
- Boston Pharmaceuticals Inc
- BriaCell Therapeutics Corp
- Bridge Biotherapeutics Inc
- BrightPath Biotherapeutics Co Ltd
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- CanBas Co Ltd
- Candel Therapeutics
- Cantargia AB
- CARsgen Therapeutics Ltd
- CAS-Lamvac Biotech Co Ltd
- Cascade Prodrug Inc
- CDR-Life Inc
- Cellatoz Therapeutics Inc
- Celldex Therapeutics Inc
- Cellestia Biotech AG
- Cellmid Ltd
- Celltrion Inc
- Cellular Biomedicine Group Inc
- Cellworks Group Inc
- Celon Pharma SA
- Centaurus Biopharma Co Ltd
- Centurion BioPharma Corp
- Centus Biotherapeutics Ltd
- Checkmate Pharmaceuticals Inc
- Checkpoint Therapeutics Inc
- Chi Cheung (Shanghai) Biomedical Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chineo Med Beijing Co Ltd
- Chiome Bioscience Inc
- Chipscreen Biosciences Ltd
- Chong Kun Dang Pharmaceutical Corp
- Chugai Pharmaceutical Co Ltd
- Cipla BioTec Pvt Ltd
- Cleveland BioLabs Inc
- Cloaked Therapeutics LLC
- Clovis Oncology Inc
- Co-D Therapeutics Inc
- Compugen Ltd
- Constellation Pharmaceuticals Inc
- Convert Pharmaceuticals SA
- Corcept Therapeutics Inc
- Cortice Biosciences Inc
- Corvus Pharmaceuticals Inc
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Cumberland Pharmaceuticals Inc
- Cureport Inc
- Cyclica Inc
- Cytocom Inc
- Cytocraft Bio-Tech Development Co Ltd
- CytomX Therapeutics Inc
- DAE HWA Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- Deciphera Pharmaceuticals Inc
- DEKK-TEC Inc
- DelMar Pharmaceuticals Inc
- Delta-Fly Pharma Inc
- DiNonA Inc
- Dizal (Jiangsu) Pharmaceutical Co Ltd
- Domainex Ltd
- Dr. Reddy's Laboratories Ltd
- Dragonfly Therapeutics Inc
- Druggability Technologies Holdings Ltd
- Dynavax Technologies Corp
- eFFECTOR Therapeutics Inc
- EirGenix Inc
- Eisai Co Ltd
- Eleison Pharmaceuticals LLC
- Eli Lilly and Co
- Elicio Therapeutics
- EnGeneIC Ltd
- Enochian Biosciences Inc
- EntreChem SL
- Enzene Biosciences Ltd
- EpicentRx Inc
- Epidestiny Inc
- EpimAb Biotherapeutics Inc
- Epizyme Inc
- Epygen Biotech Pvt Ltd
- Ergon Pharmaceuticals LLC
- Esanex Inc
- Essential Biotechnology LLC
- Eudendron Srl
- Eutilex Co Ltd
- Evaxion Biotech ApS
- Evelo Biosciences Inc
- Evestra Inc
- Evotec SE
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- FibroStatin SL
- Five Prime Therapeutics Inc
- Fochon Pharma Inc
- Fochon Pharmaceutical Ltd
- Forbius
- Formosa Pharmaceuticals Inc
- Fresenius SE & Co KGaA
- Fujifilm Holdings Corp
- G&E Corp
- G1 Therapeutics Inc
- Galectin Therapeutics Inc
- Galera Therapeutics Inc
- GC Pharma
- GEEN Biotechnology Inc
- GEMoaB Monoclonals GmbH
- Gene Techno Science Co Ltd
- GeneFrontier Corp
- Genelux Corp
- Genentech Inc
- Geneos Therapeutics Inc
- Genexine Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genmab AS
- Genocea Biosciences Inc
- Genome & Co
- Genor BioPharma Co Ltd
- Genosco Inc
- Genprex Inc
